- TLDR Biotech
- Archive
- Page 11
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | August 19 - 20, 2024
Eli Lilly's GIP/GLP-1 golden-goose reduces type 2 diabetes occurrence, J&J nabs FDA approval for first-line mAb+small molecule combo in lung cancer, Pathalys Pharma $105M Series B, Organon buys migraine med Emgality rights from Eli Lilly for multiple countries, Emergent to donate 50k smallpox vaccines, Ozempic/Wegovy use may be linked to suicidal thoughts, Teva & Biogen (separately) sued for alleged pharmacy/PBM kickbacks related to MS meds
Biotech & Pharma Updates | August 18 - 19, 2024
Walgreens and BARDA decentralized clinical trial partnership, BioNTech & MediLink ADC partial clinical hold lifted, MindBio reports positive LSD microdosing Ph2a data in depression, Avidity's $345M fundraise, TYK Medicines planned $74M HKEX IPO, Eli Lilly concludes Morphic takeover, Liquidia's tentative FDA approval collapses stock, and FDA med device recalls aren't really recalls
Biotech & Pharma Updates | August 15 - 18, 2024
AstraZeneca nabs Imfinzi perioperative lung cancer FDA approval, Novo Nordisk invests $221M in new raw materials site, Audax PE buys Avantor's CRO division while also selling healthcare consultancy to Blackstone, Gavi has $500M for mpox shot access, Pfizer & BioNTech's COVID-19/flu vaccine attempt falls short in Ph3, Genentech shutters separate cancer immunology research department
Biotech & Pharma Updates | August 14 - 15, 2024
Medicare reveals first drug price negotiations, Bavarian Nordic stock nearly doubles on mpox global health emergency concerns, Zealand Pharma searches for commercial partner for their obesity med, Abata (Treg) lands strategic investment from BMS, Bayer's restructuring (allegedly) ain't slowing down BD efforts, SIGA Tpoxx antiviral misses primary endpoint, the L's keep stacking for Lykos as they cut 75% of their staff
Biotech & Pharma Updates | August 13 - 14, 2024
Gilead snags accelerated approval for cholangitis med, Acelyrin posts positive Ph3 skin disorder data, Avidity's up to $300M public offering, Arrowhead wants to get in on obesity, Avenge Bio and Galera Therapeutics wind down, bluebird bio stocks sinks as sickle-cell gene therapy uptake moves at glacial pace, Grail and Evotec slash a combined 750 jobs, WHO declares mpox a public health emergency
Biotech & Pharma Updates | August 12 - 13, 2024
Eli Lilly opens glassy $700M Boston R&D site, Evotec handed $75M milestone from BMS, atai Life Science and Cybin want to succeed where Lykos has stumbled, Novartis heart failure generic suit fails (again), Actuate Therapeutics' underwhelming IPO, Prolific Machines nabs grant to biomanufacture mAbs for low- and middle-income countries, and Boundless Bio doesn't have boundless job openings
Biotech & Pharma Updates | August 11 - 12, 2024
J&J's talc lawsuit saga may be ending, Sandoz biosimilar approval signals fourth Eylea (Regenron) competitor, Pfizer lands immunocompromised RSV Ph3 win, Halda Therapeutics $126M Series B, $924M botox industry M&A, FibroGen to layoff 127 SF-based staffers, and there's a new "largest protein" in town
Biotech & Pharma Updates | August 8 - 11, 2024
ARS Pharmaceuticals nasal epinephrine spray FDA approved, Merck pays up to $1.3B for bispecific asset, Avidity posts positive Ph1/2 DMD data, Sandoz's Humira biosimilar keeps on making money, Cabaletta reports adverse event in CAR-T lupus trial, 23andMe tries to cash in on GLP-1 hype, and Lykos Therapeutics can't catch a break with 3 of their papers getting redacted
Biotech & Pharma Updates | August 7 - 8, 2024
Eli Lilly's stupendous Q2 results, AI-biotechs Recursion & Exscientia merge, Vertex's Casgevy reaches reimbursement deal with UK's NHS, Novartis' FDA accelerated approval for nephropathy med, Bavarian Nordic snag $150M+ BARDA contract, Sanofi's Ph3 myeloma win, Merck & Co.'s Ph3 lung cancer miss, and Sarepta's earnings disappoint investors
Biotech & Pharma Updates | August 6 - 7, 2024
Novo Nordisk posts disappointing Q2 earnings, Chugai acquires Japan rights to Roche IBD med, Amgen's Horizon acquisition continues to pay off in Q2 earnings, IDRx's $120M Series B, Pharmacosmos buys G1 Therapeutics, Novo pulls back Wegovy heart failure submission, and insider trading doesn't pay
Biotech & Pharma Updates | August 5 - 6, 2024
Agios to collect a fat $1.1B milestone payment after FDA approval, Symbiotic Capital life science credit firm launches with $600M, Shinobi Therapeutics extends Series A + lands $59M grant, Pfizer invests in antimicrobial resistance, Merck & Co. signs T-cell engager bispecific partnership with Daiichi Sankyo, Bayer touts massive management cuts over H1 2024, BioMarin shrinks Roctavian gene therapy ambitions
Biotech & Pharma Updates | August 4 - 5, 2024
Bayer posts heart failure Ph3 win, Mallinckrodt sells Therakos division to PE firm at a substantial loss, MBX Biosciences $63.5M Series C, Actinium turns to partnership after FDA rejection, BioNTech posts $883M net loss for Q2, and gene therapy biotech Lacerta Therapeutics shuts down